Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tilrekimig in Severe Asthma
NCT07772921Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Aug 2026
- Primary completion
- Jun 2029
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Treatment Arm A Tilrekimig with Treatment Arm B Placebo (2 arms). Primary endpoint: Annualized asthma exacerbation rate at 52 weeks. Started Aug 2026; status: recruiting.
02
Drugs
tilrekimig
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07772921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07772921.